Home » Topics » Disease categories and therapies » Infection

Infection
RSS

Micrologix Biotech initiates phase I trial in U.S. with MBI-226

Dec. 10, 1998

LY-303366: therapeutic and prophylactic efficacy in pulmonary aspergillosis in neutropenic animals

Dec. 9, 1998

Water-soluble antifungal agents enter the pipeline at Takeda

Dec. 8, 1998

Japanese lab prepares new, broad-spectrum carbapenems

Dec. 7, 1998

Potent antifungal triazoles reported by Sankyo

Dec. 7, 1998

Potent anti-MRSA agents developed by Sankyo

Dec. 4, 1998

Ascent to terminate copromotion agreement with Bristol-Myers Squibb

Dec. 4, 1998

Ascent to promote Warner-Lambert's Omnicef

Dec. 3, 1998

Bausch & Lomb to manufacture Lidakol for treatment of oral-facial herpes

Dec. 3, 1998

AMBI seeks partners to develop injectable nisin for treatment of hospital-acquired infections

Dec. 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...